LT2474521T - Aukšto grynumo laipsnio 2-[4-(3- ir 2-fluorbenziloksi)benzilamino]propanamidai, skirti naudoti kaip medikamentai, ir juos apimančios farmacinės kompozicijos - Google Patents

Aukšto grynumo laipsnio 2-[4-(3- ir 2-fluorbenziloksi)benzilamino]propanamidai, skirti naudoti kaip medikamentai, ir juos apimančios farmacinės kompozicijos

Info

Publication number
LT2474521T
LT2474521T LTEP12163085.9T LT12163085T LT2474521T LT 2474521 T LT2474521 T LT 2474521T LT 12163085 T LT12163085 T LT 12163085T LT 2474521 T LT2474521 T LT 2474521T
Authority
LT
Lithuania
Prior art keywords
propanamides
fluorobenzyloxy
benzylamino
medicaments
high purity
Prior art date
Application number
LTEP12163085.9T
Other languages
English (en)
Lithuanian (lt)
Inventor
Elena Barbanti
Carla Caccia
Patricia Salvati
Francesco Velardi
Tiziano Ruffilli
Luigi Bogogna
Original Assignee
Newron Pharmaceuticals S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2474521(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharmaceuticals S.P.A. filed Critical Newron Pharmaceuticals S.P.A.
Publication of LT2474521T publication Critical patent/LT2474521T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/18—Preparation of optical isomers by stereospecific synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP12163085.9T 2006-06-19 2007-06-08 Aukšto grynumo laipsnio 2-[4-(3- ir 2-fluorbenziloksi)benzilamino]propanamidai, skirti naudoti kaip medikamentai, ir juos apimančios farmacinės kompozicijos LT2474521T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06012565 2006-06-19

Publications (1)

Publication Number Publication Date
LT2474521T true LT2474521T (lt) 2016-11-25

Family

ID=37101658

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12163085.9T LT2474521T (lt) 2006-06-19 2007-06-08 Aukšto grynumo laipsnio 2-[4-(3- ir 2-fluorbenziloksi)benzilamino]propanamidai, skirti naudoti kaip medikamentai, ir juos apimančios farmacinės kompozicijos

Country Status (26)

Country Link
US (2) US8076515B2 (enExample)
EP (2) EP2029524B1 (enExample)
JP (2) JP5240476B2 (enExample)
KR (2) KR101410291B1 (enExample)
CN (2) CN101472880B (enExample)
AR (1) AR061510A1 (enExample)
AU (1) AU2007263328C1 (enExample)
BR (1) BRPI0712936B8 (enExample)
CA (1) CA2653012C (enExample)
CY (2) CY1115951T1 (enExample)
DK (2) DK2029524T3 (enExample)
EA (2) EA025326B1 (enExample)
ES (2) ES2527437T3 (enExample)
HR (2) HRP20150136T1 (enExample)
HU (1) HUE030233T2 (enExample)
IL (1) IL195294A (enExample)
LT (1) LT2474521T (enExample)
MX (2) MX342698B (enExample)
NO (2) NO342018B1 (enExample)
NZ (2) NZ595737A (enExample)
PL (2) PL2029524T3 (enExample)
PT (2) PT2474521T (enExample)
RS (2) RS55464B1 (enExample)
SI (2) SI2474521T1 (enExample)
TW (2) TWI412512B (enExample)
WO (1) WO2007147491A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1658062E (pt) * 2003-08-25 2010-03-31 Newron Pharm Spa Derivados de alfa-amino amida úteis como agentes antiinflamatórios
EA025326B1 (ru) * 2006-06-19 2016-12-30 Ньюрон Фармасьютикалс С.П.А. Применение сафинамида и ралфинамида высокой степени чистоты для лечения заболеваний и болезненных состояний в условиях, не препятствующих активности цитохромов системы cyp450 и не проявляющих блокирующих свойств в отношении herg канала
CN101896456B (zh) * 2007-12-11 2014-10-22 纽朗制药有限公司 具有高纯度的2-[4-(3-或2-氟苄氧基)苄氨基]丙酰胺类的生产方法
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
KR101851118B1 (ko) * 2010-04-27 2018-04-23 뉴론 파마슈티칼즈 에스. 피. 에이. 랄핀아미드 메탄설포네이트 염들 또는 이들의 ｒ―에난티오머들의 제조 방법
HK1209123A1 (en) 2012-12-03 2016-03-24 霍夫曼-拉罗奇有限公司 Substituted isoxazole amide compounds as inhibitors of stearoyl-coa desaturase 1 (scd1)
WO2014178083A1 (en) 2013-05-03 2014-11-06 Council Of Scientific & Industrial Research An improved synthesis of anti-parkinson agent
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
JP6466109B2 (ja) * 2014-09-09 2019-02-06 東ソー・ファインケム株式会社 ２−ベンジルオキシ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
CN105017060B (zh) * 2015-07-03 2017-06-16 南京正大天晴制药有限公司 一种沙芬酰胺新晶型及其制备方法
CN106365966A (zh) * 2015-07-24 2017-02-01 上海医药集团股份有限公司 一种苄基芳基醚的制备方法
CN105061245A (zh) * 2015-08-25 2015-11-18 成都维恒医药科技有限公司 一种高纯度沙芬酰胺的制备方法
CN106220525A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种工业化沙芬酰胺甲磺酸盐的制备方法
CN106336363B (zh) * 2016-08-22 2018-10-30 上海医药集团股份有限公司 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
CN106565521B (zh) * 2016-08-24 2019-03-08 浙江美诺华药物化学有限公司 (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
CN106596828B (zh) * 2016-12-15 2018-09-25 扬子江药业集团有限公司 一种甲磺酸沙芬酰胺有关物质的检测方法
CN107271600B (zh) * 2017-07-28 2019-01-25 成都百裕制药股份有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体杂质含量的检测方法
CN107759487A (zh) * 2017-11-23 2018-03-06 江苏恒盛药业有限公司 一种沙芬酰胺盐酸盐及其一种晶型以及制备方法
CN107857713A (zh) * 2017-11-23 2018-03-30 江苏恒盛药业有限公司 一种沙芬酰胺氢溴酸盐及其一种晶型
WO2019167085A1 (en) * 2018-03-01 2019-09-06 Msn Laboratories Private Limited, R&D Center Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate
US11111208B2 (en) 2019-06-17 2021-09-07 RK Pharma Solutions LLC Process for the preparation of safinamide mesylate intermediate
US11225457B2 (en) 2019-08-06 2022-01-18 Medichem, S.A. Process for preparing safinamide
CN111122736B (zh) * 2019-12-30 2021-03-12 北京鑫开元医药科技有限公司海南分公司 一种用于检测布瓦西坦中间体中对映异构体的方法
CN113214097B (zh) * 2020-01-21 2022-08-30 厦门大学 治疗阿尔茨海默病的化合物
CN112028754A (zh) * 2020-06-17 2020-12-04 浙江美诺华药物化学有限公司 一种甲磺酸沙芬酰胺中间体的制备方法
CN114088830B (zh) * 2021-11-10 2022-09-23 石家庄四药有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体的检测方法
CN116008439B (zh) * 2023-02-20 2023-10-27 山东绿叶制药有限公司 一种检测2,6-二氧杂螺[4,5]癸烷类化合物或其盐中杂质的方法
WO2025022300A1 (en) 2023-07-25 2025-01-30 Intas Pharmaceuticals Ltd. An orodispersible pharmaceutical solid dosage form of safinamide

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
IL151952A0 (en) 2000-03-31 2003-04-10 Euro Celtique Sa Aminopyridine derivatives and pharmaceutical compositions containing the same
ATE317280T1 (de) 2001-09-03 2006-02-15 Newron Pharm Spa Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
US20040213842A1 (en) * 2003-01-30 2004-10-28 Dynogen Pharmaceuticals, Inc. Methods of treating gastrointestinal tract disorders using sodium channel modulators
JP2006515327A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド ナトリウムチャネル調節因子を用いた下部尿路障害を処置するための方法
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
PT1658062E (pt) 2003-08-25 2010-03-31 Newron Pharm Spa Derivados de alfa-amino amida úteis como agentes antiinflamatórios
EP1524267A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Substituted benzylaminoalkylene heterocycles
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
KR101277520B1 (ko) 2004-09-10 2013-06-21 뉴론 파마슈티칼즈 에스. 피. 에이. （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
EA025326B1 (ru) * 2006-06-19 2016-12-30 Ньюрон Фармасьютикалс С.П.А. Применение сафинамида и ралфинамида высокой степени чистоты для лечения заболеваний и болезненных состояний в условиях, не препятствующих активности цитохромов системы cyp450 и не проявляющих блокирующих свойств в отношении herg канала
CN101896456B (zh) 2007-12-11 2014-10-22 纽朗制药有限公司 具有高纯度的2-[4-(3-或2-氟苄氧基)苄氨基]丙酰胺类的生产方法
EA019529B1 (ru) 2007-12-19 2014-04-30 Ньюрон Фармасьютикалс С.П.А. Альфа-аминоамидные производные, применяемые в лечении психиатрических расстройств

Also Published As

Publication number Publication date
HK1130245A1 (en) 2009-12-24
CY1115951T1 (el) 2017-01-25
TW200815322A (en) 2008-04-01
US20090156678A1 (en) 2009-06-18
BRPI0712936B8 (pt) 2021-05-25
BRPI0712936A2 (pt) 2012-12-18
NO342018B1 (no) 2018-03-12
EA017123B1 (ru) 2012-10-30
US8278485B2 (en) 2012-10-02
PT2474521T (pt) 2016-11-10
CA2653012A1 (en) 2007-12-27
MX2008015704A (es) 2009-01-09
KR101491541B1 (ko) 2015-02-09
CN101472880A (zh) 2009-07-01
RS55464B1 (sr) 2017-04-28
US8076515B2 (en) 2011-12-13
JP5240476B2 (ja) 2013-07-17
CN101472880B (zh) 2013-04-24
CN103284984B (zh) 2016-08-03
ES2602069T3 (es) 2017-02-17
EP2474521A1 (en) 2012-07-11
EA025326B1 (ru) 2016-12-30
RS53824B1 (sr) 2015-06-30
PL2474521T3 (pl) 2017-01-31
KR101410291B1 (ko) 2014-06-20
AU2007263328A1 (en) 2007-12-27
HRP20161456T1 (hr) 2016-12-16
HRP20150136T1 (xx) 2015-03-13
SI2474521T1 (sl) 2016-12-30
US20120157712A1 (en) 2012-06-21
AU2007263328B2 (en) 2012-03-22
SI2029524T1 (sl) 2015-03-31
TW201313662A (zh) 2013-04-01
NZ595737A (en) 2013-04-26
AR061510A1 (es) 2008-09-03
IL195294A (en) 2015-03-31
DK2029524T3 (da) 2015-02-23
NO20090231L (no) 2009-01-16
TWI412512B (zh) 2013-10-21
NO342644B1 (no) 2018-06-25
KR20090021392A (ko) 2009-03-03
JP2013139446A (ja) 2013-07-18
AU2007263328C1 (en) 2012-09-06
ES2527437T3 (es) 2015-01-26
PL2029524T3 (pl) 2015-04-30
PT2029524E (pt) 2015-03-09
IL195294A0 (en) 2009-08-03
EP2029524B1 (en) 2014-11-26
MX342698B (es) 2016-10-10
WO2007147491A1 (en) 2007-12-27
JP5795342B2 (ja) 2015-10-14
CN103284984A (zh) 2013-09-11
NO20171916A1 (no) 2009-01-16
KR20140027563A (ko) 2014-03-06
NZ572798A (en) 2011-11-25
TWI393700B (zh) 2013-04-21
JP2009541232A (ja) 2009-11-26
HUE030233T2 (en) 2017-04-28
EP2474521B1 (en) 2016-08-10
CY1118113T1 (el) 2017-06-28
EA200970028A1 (ru) 2009-06-30
EP2029524A1 (en) 2009-03-04
EA201101308A1 (ru) 2012-02-28
CA2653012C (en) 2014-08-05
BRPI0712936B1 (pt) 2021-02-23
DK2474521T3 (en) 2016-10-31
AU2007263328A2 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
PT2474521T (pt) 2-[4-(3- e 2-fluorobenziloxi)benzilamino]propanamidas de grau de pureza elevado para utilização como medicamentos e formulações farmacêuticas que as contêm
IL205872A (en) Process for the preparation of compounds 2- [4- (3- or 2-fluorobenzyloxy) benzylamino] high-purity propanamide, medicinal preparations containing them, and their use in the preparation of drugs
IL185277A0 (en) Pharmaceutical compositions containing roflumilast for the treatment of diabetes
IL193894A0 (en) Pharmaceutical compositions containing luliconazole for external use
IL212435A (en) Isoindulin compounds, their pharmaceutical compositions and their use in the preparation of drugs
IL193762A (en) The effective compounds in inhibiting dgat1-related disorders, their medicinal products and their use in the preparation of drugs
IL199397A (en) Hetero-ring compounds, pharmaceuticals containing them, and their medicinal products
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
ZA200900345B (en) Preparation of pharmaceutical formulations
IL201581A0 (en) Pharmaceutical formulations containing lipoic acid derivatives
IL198301A (en) Aryl amides are stored in thiazole and oxazole, a pharmaceutical preparation containing them and their use in the preparation of drugs
IL209054A0 (en) Solid pharmaceutical formulations comprising bibw 2992
ZA200808530B (en) Pharmaceutical composition for external use
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
IL205742A (en) 4 - (4-Cyano-2-Theoaryl) dihydropyrimidinones, their preparation processes, medications containing them and their use
IL212573A (en) Aryl Methyl Benzokinazulinone Compounds
IL195947A (en) Manicured cyclic compounds and pharmaceutical preparations containing them for use @ for prevention @ and treatment @ for diabetes
ZA200810166B (en) Phenylephrine pharmaceutical formulations and compositions for colonic absorption
IL199362A (en) Pyridopyrimidine Compounds, Pharmaceuticals, Compounds for Use as a Drug, and Compounds for Manufacture @ Drug
IL188980A0 (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
SI1874746T1 (sl) Derivati 1-N-azacikloalkil-3-fenoksipropana za uporabo pri pripravi psihotropičnih zdravil
IL206562A0 (en) Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition
IL218745A0 (en) Pharmaceutical compositions containing roflumilast
ZA200807486B (en) Medicament formulations comprising fluoroquinolones